Prenatal administration of Betamethasone causes changes in the T cell receptor repertoire influencing Development of autoimmunity


Por: Gieras, A, Gehbauer, C, Perna-Barrull, D, Engler, JB, Diepenbruck, I, Glau, L, Joosse, SA, Kersten, N, Klinge, S, Mittrucker, HW, Friese, MA, Vives-Pi, M and Tolosa, E

Publicada: 13 nov 2017
Resumen:
Prenatal glucocorticoids are routinely administered to pregnant women at risk of preterm delivery in order to improve survival of the newborn. However, in half of the cases, birth occurs outside the beneficial period for lung development. Glucocorticoids are potent immune modulators and cause apoptotic death of immature T cells, and we have previously shown that prenatal betamethasone treatment at doses eliciting lung maturation induce profound thymocyte apoptosis in the offspring. Here, we asked if there are long-term consequences on the offspring's immunity after this treatment. In the non-obese diabetic mouse model, prenatal betamethasone clearly decreased the frequency of pathogenic T cells and the incidence of type 1 diabetes (T1D). In contrast, in the lupus-prone MRL/lpr strain, prenatal glucocorticoids induced changes in the T cell repertoire that resulted in more autoreactive cells. Even though glucocorticoids transiently enhanced regulatory T cell (Treg) development, these cells did not have a protective effect in a model for multiple sclerosis which relies on a limited repertoire of pathogenic T cells for disease induction that were not affected by prenatal betamethasone. We conclude that prenatal steroid treatment, by inducing changes in the T cell receptor repertoire, has unforeseeable consequences on development of autoimmune disease. Our data should encourage further research to fully understand the consequences of this widely used treatment.

Filiaciones:
Gieras, A:
 Univ Med Ctr Hamburg Eppendorf, Dept Immunol, Hamburg, Germany

Gehbauer, C:
 Univ Med Ctr Hamburg Eppendorf, Dept Immunol, Hamburg, Germany

:
 Univ Autonoma Barcelona, Germans Trias i Pujol Res Inst & Hosp, Immunol Div, Badalona, Spain

Engler, JB:
 Ctr Mol Neurobiol Hamburg, Inst Neuroimmunol & Multiple Sclerosis, Hamburg, Germany

Diepenbruck, I:
 Univ Med Ctr Hamburg Eppendorf, Dept Immunol, Hamburg, Germany

Glau, L:
 Univ Med Ctr Hamburg Eppendorf, Dept Immunol, Hamburg, Germany

Joosse, SA:
 Univ Med Ctr Hamburg Eppendorf, Dept Tumor Biol, Hamburg, Germany

Kersten, N:
 Univ Med Ctr Hamburg Eppendorf, Dept Immunol, Hamburg, Germany

Klinge, S:
 Univ Med Ctr Hamburg Eppendorf, Dept Immunol, Hamburg, Germany

Mittrucker, HW:
 Univ Med Ctr Hamburg Eppendorf, Dept Immunol, Hamburg, Germany

Friese, MA:
 Ctr Mol Neurobiol Hamburg, Inst Neuroimmunol & Multiple Sclerosis, Hamburg, Germany

:
 Univ Autonoma Barcelona, Germans Trias i Pujol Res Inst & Hosp, Immunol Div, Badalona, Spain

 Inst Salud Carlos III, Ctr Invest Biomed Red Diabet & Enfermedades Metab, Madrid, Spain

Tolosa, E:
 Univ Med Ctr Hamburg Eppendorf, Dept Immunol, Hamburg, Germany
ISSN: 16643224





Frontiers in Immunology
Editorial
Frontiers Media S.A., AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND, Suiza
Tipo de documento: Article
Volumen: 8 Número:
Páginas:
WOS Id: 000414907300001
ID de PubMed: 29181000
imagen Green Published, gold

MÉTRICAS